A5006123817- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Chronic Lymphocytic Leukemia Research
- Autoimmune and Inflammatory Disorders Research
- Lymphoma Diagnosis and Treatment
- Systemic Sclerosis and Related Diseases
- Monoclonal and Polyclonal Antibodies Research
- Spondyloarthritis Studies and Treatments
- Biosimilars and Bioanalytical Methods
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Immunodeficiency and Autoimmune Disorders
- Inflammatory Myopathies and Dermatomyositis
- HER2/EGFR in Cancer Research
- Chronic Myeloid Leukemia Treatments
- Musculoskeletal pain and rehabilitation
- Adolescent and Pediatric Healthcare
- Bone and Joint Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Peripheral Neuropathies and Disorders
- Cytokine Signaling Pathways and Interactions
- Bone health and treatments
- Health Systems, Economic Evaluations, Quality of Life
- Hepatitis C virus research
- Dermatologic Treatments and Research
- Autoimmune Bullous Skin Diseases
KU Leuven
2016-2025
Universitair Ziekenhuis Leuven
2014-2024
Xiangya Hospital Central South University
2023
Central South University
2023
Harvard University
2023
Massachusetts General Hospital
2023
Canterbury Christ Church University
2023
Tanta University
2023
Rijksinstituut voor Ziekte- en Invaliditeitsverzekering
2018
University of Manchester
2005-2017
To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for most recent developments in field.An international task force considered new evidence supporting or contradicting previous and novel therapies strategic insights based on two systematic literature searches efficacy safety disease-modifying antirheumatic drugs (DMARDs) since last (2016) until 2019. A predefined voting process was applied, current levels...
Osteoporosis is a common complication of long-term glucocorticoid therapy for which there no well-proved preventive or restorative treatment.
Effective new therapies are needed for rheumatoid arthritis. Current target the products of activated macrophages; however, T cells also have an important role in A fusion protein — cytotoxic T-lymphocyte–associated antigen 4–IgG1 (CTLA4Ig) is first a class drugs known as costimulation blockers being evaluated treatment CTLA4Ig binds to CD80 and CD86 on antigen-presenting cells, blocking engagement CD28 preventing T-cell activation. preliminary study showed that may be effective
<h3>Objectives</h3> To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing most recent developments in field. <h3>Methods</h3> An international task force was formed and solicited three systematic literature research activities on safety efficacy disease-modifying antirheumatic drugs (DMARDs) glucocorticoids (GCs). The new evidence discussed light last from 2019. A predefined voting process applied to each overarching principle recommendation....
Background: The selective co-stimulation modulator abatacept demonstrated efficacy for treating rheumatoid arthritis in early clinical studies. Objective: To evaluate the effects of patients with persistent, active despite methotrexate treatment. Design: One-year, multicenter, randomized, double-blind, placebo-controlled trial (November 2002 to October 2004). Setting: 116 centers worldwide. Patients: 652 Intervention: Once-monthly infusion a fixed dose abatacept, approximately 10 mg/kg body...
High-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation (HSCT) have shown efficacy in systemic sclerosis phase 1 small 2 trials.To compare safety of HSCT vs 12 successive monthly intravenous pulses cyclophosphamide.The Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, a 3, multicenter, randomized (1:1), open-label, parallel-group, clinical trial conducted 10 countries at 29 centers with access to European Group for Blood Marrow...
Abstract Objective The Combinatietherapie Bij Reumatoide Artritis (COBRA) trial demonstrated that step‐down combination therapy with prednisolone, methotrexate, and sulfasalazine (SSZ) was superior to SSZ monotherapy for suppressing disease activity radiologic progression of rheumatoid arthritis (RA). current study conducted investigate whether the benefits COBRA were sustained over time, determine which baseline factors could predict outcome. Methods All patients had participated in 56‐week...
To evaluate the continued efficacy and safety of alendronate (ALN) for up to 2 years in patients receiving glucocorticoids.This is a 12-month extension previously completed 1-year trial daily ALN, performed effects ALN over total 66 men 142 women continuing receive at least 7.5 mg prednisone or equivalent daily. All received supplemental calcium vitamin D. The primary end point was mean percentage change lumbar spine bone mineral density (BMD) from baseline 24 months. Other outcomes included...
<h3>Objective:</h3> To develop evidence-based recommendations for the management of systemic glucocorticoid (GC) therapy in rheumatic diseases. <h3>Methods:</h3> The multidisciplinary guideline development group from 11 European countries, Canada and USA consisted 15 rheumatologists, 1 internist, rheumatologist–epidemiologist, health professional, patient research fellow. Delphi method was used to agree on 10 key propositions related safe use GCs. A systematic literature search PUBMED,...
Abstract Objective To evaluate abatacept therapy in patients with non–life‐threatening systemic lupus erythematosus (SLE) and polyarthritis, discoid lesions, or pleuritis and/or pericarditis. Methods In a 12‐month, multicenter, exploratory, phase IIb randomized, double‐blind, placebo‐controlled trial, SLE pericarditis were randomized at ratio of 2:1 to receive (∼10 mg/kg body weight) placebo. Prednisone (30 mg/day equivalent) was given for 1 month, then the dosage tapered. The primary end...
<h3>Objectives:</h3> To assess the efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis (RA) poor prognostic factors. <h3>Methods:</h3> In this double-blind, phase IIIb study, RA for 2 years or less were randomly assigned 1 : to receive (∼10 mg/kg) plus methotrexate, placebo methotrexate. Patients seropositive factor (RF), anti-cyclic citrullinated protein (CCP) type both had radiographic evidence joint erosions. The co-primary endpoints proportion...
Abstract Objective To assess the risk of serious infections following 22 weeks infliximab therapy, and to further characterize safety profile in combination with background treatments during 1 year patients rheumatoid arthritis (RA) various comorbidities. Methods Patients active RA despite receiving methotrexate (MTX) were randomly assigned receive infusions placebo (group 1, n = 363), 3 mg/kg 2, 360), or 10 3, 361) at 0, 6, 14. At week 22, group began infliximab, continued an dose mg/kg. 2...
To develop recommendations for the management of medium to high-dose (ie, >7.5 mg but ≤100 prednisone equivalent daily) systemic glucocorticoid (GC) therapy in rheumatic diseases. A multidisciplinary EULAR task force was formed, including patients. After discussing results a general initial search on risks GC therapy, each participant contributed 10 propositions key clinical topics concerning safe use GCs. The final were selected via Delphi consensus approach. systematic literature...
The aim of this study was to determine, through a genome-wide association (GWAS), the genetic components contributing different clinical sub-phenotypes systemic sclerosis (SSc). We considered limited (lcSSc) and diffuse (dcSSc) cutaneous involvement, relationships with presence SSc-specific auto-antibodies, anti-centromere (ACA), anti-topoisomerase I (ATA). Four GWAS cohorts, comprising 2,296 SSc patients 5,171 healthy controls, were meta-analyzed looking for associations in selected...
Objectives To evaluate the efficacy and safety of different doses regimens filgotinib, an oral Janus kinase 1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) inadequate response MTX. Methods In this 24-week phase IIb study, moderate-to-severe RA receiving a stable dose MTX were randomised (1:1:1:1:1:1:1) receive placebo or 50, 100 200 mg administered once daily twice daily. Primary end point was percentage achieving week 12 American...
Objectives To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in patients with active rheumatoid arthritis (RA) limited or no prior methotrexate (MTX) exposure. Methods This 52-week, phase 3, multicentre, double-blind clinical trial ( NCT02886728 ) evaluated once-daily oral 1252 RA randomised 2:1:1:2 to 200 mg MTX (FIL200 +MTX), 100 (FIL100 monotherapy (FIL200), MTX. The primary endpoint was proportion achieving 20% improvement American College Rheumatology...
Background Several agents provide treatment for established rheumatoid arthritis (RA), but a crucial therapeutic goal is to delay/prevent progression of undifferentiated (UA) or very early RA. Objective To determine the impact T-cell costimulation modulation in patients with UA Methods In this double-blind, phase II, placebocontrolled, 2-year study, anti-cyclic citrullinated peptide (CCP)2-positive (not fulfilling ACR criteria RA) and clinical synovitis two more joints were randomised...
Objective To develop recommendations on monitoring for adverse events (AEs) of low-dose glucocorticoid (GC) therapy (≤7.5 mg prednisone or equivalent daily) in clinical trials and daily practice. Methods Literature was searched articles containing information incidence GC-related AEs using PubMed, EMBASE Cochrane databases. Second, the authors broad accepted guidelines certain (eg, WHO screening diabetes). Available data were summarised discussed among experts (rheumatologists patients)...
Abstract Objective To evaluate the efficacy, radiographic changes, and safety of abatacept methotrexate therapy through 2 years in a long‐term extension previously published 1‐year study. Methods Patients who received placebo during year 1 were switched to abatacept. taking continued take it. Efficacy assessed years. Results Of 539 patients enrolled initial study, 488 completed (2% discontinued for lack efficacy). At years, had maintained their responses on American College Rheumatology...
Objectives The authors aim to develop European League Against Rheumatism recommendations for the role of nurse in management patients with chronic inflammatory arthritis, identify a research agenda and determine an educational agenda. Methods A task force made up multidisciplinary expert panel including nurses, rheumatologists, occupational therapist, physiotherapist, psychologist, epidemiologist patient representatives, representing 14 countries, carried out development recommendations,...